Oncotarget

Research Papers:

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)

Dok Hyun Yoon, Byeong Seok Sohn, Sung Yong Oh, Won-Sik Lee, Sang Min Lee, Deok-Hwan Yang, Jooryung Huh and Cheolwon Suh _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:13367-13374. https://doi.org/10.18632/oncotarget.14531

Metrics: PDF 2182 views  |   HTML 2563 views  |   ?  


Abstract

Dok Hyun Yoon1,*, Byeong Seok Sohn2,*, Sung Yong Oh3, Won-Sik Lee4, Sang Min Lee4, Deok-Hwan Yang5, Jooryung Huh6, Cheolwon Suh1

1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea

3Department of Internal Medicine, Dong-A University Hospital, Busan, Korea

4Department of Hemato-Oncology, Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

5Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea

6Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

*These authors have contributed equally to this work

Correspondence to:

Cheolwon Suh, email: [email protected]

Dok Hyun Yoon, email: [email protected]

Keywords: diffuse large B-cell lymphoma, limited stage, complete resection, abbreviated cycles and R-CHOP chemotherapy

Received: November 04, 2016     Accepted: December 28, 2016     Published: January 05, 2017

ABSTRACT

Background: The appropriate number of chemotherapy cycles for limited stage diffuse large B-cell lymphoma (DLBCL) patients without gross residual lesions after complete resection, has not been specifically questioned. We performed a multicenter, single-arm, phase 2 study to investigate the feasibility of 3 cycles of abbreviated R-CHOP chemotherapy in low-risk patients with completely resected localized CD20+ DLBCL.

Results: Between December 2010 and May 2013, we recruited 23 patients. One was excluded due to ineligibility, and hence, 22 were included in the final analysis. The primary sites comprised the intestine (n = 15), cervical lymph nodes (n = 4), stomach (n = 1), tonsil (n = 1), and spleen (n = 1). All patients successfully completed the 3 cycles of planned R-CHOP chemotherapy. Over a median follow-up of 39.5 months (95% confidence interval, 29.9—47.1 months), both the estimated 2-year disease-free survival and overall survival rates was 95% confidence interval, 85.9–104.1%. Only one patient with an international prognostic index of 2 experienced relapse and died. The most common grade 3 or 4 toxicity condition included neutropenia (n = 8, 36.4%). Three patients experienced grade 3 febrile neutropenia, but no grade 3 or 4 non-hematologic toxicity was observed.

Materials and Methods: DLBCL patients without residual lesions after resection were enrolled and R-CHOP chemotherapy was repeated at 3-week-intervals over 3 cycles. The primary endpoint was 2-year disease-free survival.

Conclusions: Three cycles of abbreviated R-CHOP immunochemotherapy is feasible for completely resected low risk localized DLBCL.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14531